Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CET
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
11/23 JOHNSON & JOHNSON : FDA approves first-ever two-drug HIV regimen, GSK`s Juluca
11/22 JOHNSON & JOHNSON : Janssen Global Services, LLC - European Commission Extends L..
11/22 JOHNSON & JOHNSON : to Participate in the Citi 2017 Global Healthcare Conference
11/22 JOHNSON & JOHNSON : Janssen Announces U.S. FDA Approval of First and Only Comple..
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/21 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
11/21 JOHNSON & JOHNSON : California Judge Tosses Out $417 Million Verdict in Talc-Ova..
11/21 JOHNSON & JOHNSON : A Win for Johnson & Johnson in Baby Powder-Mesothelioma Case
11/20 JOHNSON & JOHNSON : to Participate in the Citi 2017 Global Healthcare Conference
11/20 JOHNSON & JOHNSON : New Real-World Analysis Shows INVOKANA® (canagliflozin) and ..
More news
News from SeekingAlpha
11/22 Dividend Kings' Share Price And Dividend Growth Plus Two Kings On Sale
11/22 102 Dividend Growth Stocks Going Ex-Dividend Next Week
11/22 KURA ONCOLOGY : Expecting Continued Appreciation In 2018
11/22 How To Start An Education Fund For Your Kids
11/22 A Simple Way To Analyze Berkshire Hathaway Holdings
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,44%
P/E ratio 2017 23,02
P/E ratio 2018 18,94
EV / Sales 2017 5,06x
EV / Sales 2018 4,66x
Capitalization 369 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.75%219 874
ROCHE HOLDING LTD.4.90%215 394
PFIZER9.42%211 188
MERCK AND COMPANY-7.64%148 286
AMGEN16.16%123 376